Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
$3.25
+0.8%
$2.97
$1.05
$3.97
$362.25M1.92712,621 shs724,346 shs
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$2.05
-1.0%
$2.25
$0.40
$3.10
$341.37M2.133.92 million shs1.58 million shs
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
$0.24
-4.3%
$1.72
$0.22
$7.88
$11.62M1.5515.65 million shs10.19 million shs
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$27.88
+1.8%
$21.24
$10.81
$28.16
$396.89M0.24103,597 shs126,178 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
+0.62%+4.51%+12.87%+4.68%+10.75%
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
-0.97%+0.99%-8.89%-18.65%+76.72%
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
-4.32%-87.76%-87.43%-86.01%-95.52%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
+1.75%+15.40%+14.92%+105.60%+99.71%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
1.3776 of 5 stars
3.51.00.00.00.60.80.6
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
4.218 of 5 stars
3.51.00.04.72.81.71.3
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
3.2502 of 5 stars
3.03.00.00.03.13.31.3
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
1.6412 of 5 stars
0.03.00.04.62.12.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
3.00
Buy$7.75138.83% Upside
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
3.00
Buy$5.75180.49% Upside
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
2.00
Hold$2.00751.06% Upside
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
2.00
HoldN/AN/A

Current Analyst Ratings Breakdown

Latest EPIX, INBX, ADCT, and CTMX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/22/2025
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform
8/13/2025
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
7/31/2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$7.00
6/20/2025
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeOutperform ➝ Moderate Buy$8.00 ➝ $5.00
6/13/2025
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $10.00
(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
$70.84M5.15N/AN/A($1.77) per share-1.83
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$138.10M2.45$0.36 per share5.72$0.73 per share2.81
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
N/AN/AN/AN/A$2.30 per shareN/A
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$1.40M288.46$121.22 per share0.23$4.73 per share5.89
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
-$157.85M-$1.57N/AN/AN/A-220.00%N/A-53.73%11/6/2025 (Estimated)
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$31.87M$0.563.66N/AN/A34.04%158.70%36.04%11/6/2025 (Estimated)
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
-$28.54M-$0.56N/AN/AN/AN/A-21.71%-21.22%N/A
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$1.69B-$10.58N/AN/AN/AN/A-137.83%-76.31%11/13/2025 (Estimated)

Latest EPIX, INBX, ADCT, and CTMX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q3 2025
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
-$0.17-$0.09+$0.08-$0.09N/AN/A
8/13/2025Q2 2025
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-$2.92-$1.85+$1.07-$1.85N/A$1.30 million
8/12/2025Q2 2025
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
-$0.36-$0.50-$0.14-$0.50$17.82 million$18.84 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
N/AN/AN/AN/AN/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
N/AN/AN/AN/AN/A
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
N/AN/AN/AN/AN/A
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
N/AN/AN/AN/AN/A

Latest EPIX, INBX, ADCT, and CTMX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/1/2100
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
--$1.698/25/20258/19/20258/22/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
N/A
4.93
4.66
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
N/A
4.20
4.20
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
N/A
69.06
69.06
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
1.45
4.98
4.98

Institutional Ownership

CompanyInstitutional Ownership
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
41.10%
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
67.77%
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
75.12%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
82.46%

Insider Ownership

CompanyInsider Ownership
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
5.40%
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
6.60%
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
15.50%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
17.09%
CompanyEmployeesShares OutstandingFree FloatOptionable
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
310112.50 million106.42 millionOptionable
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
170164.91 million154.03 millionOptionable
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
5047.31 million39.98 millionOptionable
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
16614.49 million12.01 millionOptionable

Recent News About These Companies

Inhibrx Biosciences Reports Q2 2025 Financial Results
Inhibrx Reports Second Quarter 2025 Financial Results
Inhibrx Biosciences, Inc. (INBX) - Yahoo Finance
Inhibrx Biosciences Inc (INBX) - Investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADC Therapeutics stock logo

ADC Therapeutics NYSE:ADCT

$3.24 +0.03 (+0.78%)
Closing price 08/28/2025 03:59 PM Eastern
Extended Trading
$3.26 +0.02 (+0.62%)
As of 08/28/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

CytomX Therapeutics stock logo

CytomX Therapeutics NASDAQ:CTMX

$2.05 -0.02 (-0.97%)
Closing price 08/28/2025 04:00 PM Eastern
Extended Trading
$2.12 +0.07 (+3.17%)
As of 08/28/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

ESSA Pharma stock logo

ESSA Pharma NASDAQ:EPIX

$0.24 -0.01 (-4.32%)
Closing price 08/28/2025 04:00 PM Eastern
Extended Trading
$0.23 0.00 (-2.13%)
As of 04:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Inhibrx Biosciences stock logo

Inhibrx Biosciences NASDAQ:INBX

$27.88 +0.48 (+1.75%)
Closing price 08/28/2025 04:00 PM Eastern
Extended Trading
$27.88 0.00 (0.00%)
As of 08/28/2025 04:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.